seattle genetics inc (SGEN) Key Developments
Seattle Genetics and Bristol-Myers Squibb Announce Clinical Collaboration to Evaluate Combination of Adcetris® (Brentuximab Vedotin) and Opdivo® (Nivolumab) in Hematologic Malignancies
Jan 12 15
Seattle Genetics Inc. and Bristol-Myers Squibb Company announced that the companies have entered into a clinical trial collaboration agreement to evaluate the investigational combination of Seattle Genetics’ antibody-drug conjugate (ADC) Adcetris (brentuximab vedotin) and Bristol-Myers Squibb’s immunotherapy Opdivo (nivolumab) in two planned Phase 1/2 clinical trials. The first trial will evaluate the combination of Adcetris and Opdivo as a potential treatment option for patients with relapsed or refractory Hodgkin lymphoma (HL), and the second trial will focus on patients with relapsed or refractory B-cell and T-cell non-Hodgkin lymphomas (NHL), including diffuse large B-cell lymphoma (DLBCL). Adcetris is an ADC directed to CD30, a defining marker of classical HL, which combines the targeting ability of a monoclonal antibody with the potency of a cell-killing agent. Opdivo is a human programmed death receptor-1 (PD-1) blocking antibody that binds to the PD-1 receptor expressed on activated T-cells. The studies are expected to begin in 2015, with Seattle Genetics conducting the HL trial and Bristol-Myers Squibb conducting the NHL trial. Additional details of the collaboration were not disclosed.
Seattle Genetics Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-12-2015 11:30 AM
Jan 6 15
Seattle Genetics Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-12-2015 11:30 AM. Venue: Westin St. Francis Hotel, San Francisco, California, United States. Speakers: Clay B. Siegall, Co-Founder, Chairman, Chief Executive Officer and President.
Seattle Genetics Inc. Announces Encouraging Data from Phase I AML Trial
Jan 1 15
Seattle Genetics Inc. announced data from an ongoing Phase I clinical trial evaluating SGN-CD33A, an antibody-drug conjugate, or ADC, in development for the treatment of acute myeloid leukemia, or AML. SGN-CD33A is a novel ADC targeted to CD33 utilizing Seattle Genetics' newest technology. CD33 is expressed on most AML cells regardless of subtype, cytogenetic abnormality or underlying mutational heterogeneity. SGN-CD33A is the first ADC utilizing an engineered cysteine antibody (EC-mAb) and pyrrolobenzodiazepine (PBD) dimer to be advanced into the clinic.
Seattle Genetics Inc. Announces Encouraging Data from Phase I Hodgkin Lymphoma Trial
Jan 1 15
Seattle Genetics Inc. announced data which include encouraging long-term outcomes from a Phase I trial evaluating ADCETRIS, or brentuximab vedotin, in combination with AVD chemotherapy in frontline Hodgkin lymphoma, or HL, as well as strong activity evaluating ADCETRIS combination therapy in second-line HL and ADCETRIS monotherapy or combination therapy in frontline HL patients age 60 and older. ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, which is expressed in classical HL and systemic anaplastic large cell lymphoma (sALCL), a type of T-cell lymphoma. This Phase I trial was conducted to evaluate ADCETRIS plus the chemotherapy regimen ABVD (Adriamycin, bleomycin, vinblastine and dacarbazine) or ADCETRIS plus AVD, which removes bleomycin, for the treatment of newly diagnosed advanced stage HL patients. Data previously presented from this trial demonstrated that 24 of 25 patients (96%) who received ADCETRIS plus AVD achieved a complete remission and 21 of 22 patients (95%) who completed therapy with ADCETRIS plus ABVD achieved a complete remission. The most common adverse events of any grade occurring in more than 30% of patients across both treatment regimens were hair loss, constipation, diarrhea, fatigue, insomnia, nausea, neutropenia, peripheral sensory neuropathy, fever and vomiting. As previously reported, pulmonary toxicity was seen in the ADCETRIS plus ABVD cohorts, resulting in a contraindication for the concomitant administration of ADCETRIS and bleomycin. No pulmonary toxicity was observed in the ADCETRIS plus AVD cohort. Long-term data include: In the ADCETRIS plus AVD arm, three-year overall survival was 100% and three-year failure-free survival was 92%. In the ADCETRIS plus ABVD arm, three-year overall survival was 92% and three-year failure-free survival was 79%; and Patients were followed for a median of 36 months in the ADCETRIS plus AVD arm and 45 months in the ADCETRIS plus ABVD arm.
Seattle Genetics Inc. Announces Encouraging Data from Phase II DLBCL Trials
Jan 1 15
Seattle Genetics Inc. announced encouraging data from Phase II clinical trials for ADCETRIS in patients with relapsed/refractory and frontline diffuse large B-cell lymphoma, or DLBCL. ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, which is expressed in classical Hodgkin lymphoma, anaplastic large cell lymphoma and several other types of non-Hodgkin lymphoma. The activity observed supports plans to initiate a randomized Phase II clinical trial of ADCETRIS for relapsed CD30-positive DLBCL patients during 2015 and to pursue possible frontline DLBCL combination trials." An ongoing Phase II clinical trial in relapsed or refractory DLBCL includes three treatment arms to evaluate ADCETRIS in CD30-positive disease, CD30-undetectable disease and in combination with Rituxan (rituximab).